Replies to post #53320 on Anavex Life Sciences Corp (AVXL)

[hurley999s]

The 12 week data was not "new"...if you were around for CTAD, recall that this interim analysis was included in that presentation. The 12 week data expected this quarter is for the all patients, whereas what was presented at CTAD was a subset of just the 14 who had reached 12 weeks at that point.

Here is the Nov CTAD presentation. See slide 15: MacFarlane CTAD 2015

[imho]

For now we have a positive from slide 9 to hang our hats on. Interim Data Anavex 2-73 increases ADCS-ADL by +3.21 points from baseline at 12 weeks.

Agree this is positive, because they are setting us up to believe that the full 32 patient data will be at least as good. This data will come out at a scientific conference soon and will have a higher impact on the SP. Interim 26 week data should also be released at that time. If that data follows along the same path, it will be very positive. Full 26 week data in July (I believe) will get many fence sitters to jump in or out. I am slightly more optimistic, but remain cautious.

IMHO